Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
Research finds that TRPM7 protein plays a critical role in breast cancer cell metastasis. High levels of TRPM7 expression are associated with poor patient outcomes and increased risk of distant metastases. The study suggests that targeting this protein could block metastasis, offering new therapeutic opportunities.
Researchers found that CCR9 is abundant in early stage colon cancer but lacks in invasive and metastatic cancer, suggesting its role in reducing cancer spread. Activation of NOTCH promotes degradation of CCR9, inhibiting the chemokine-induced signaling pathway.
Researchers discover antibodies to malaria surface protein PfEMP1 mediate human immunity; CCL25 pathway suppresses colon cancer metastasis; and a retargeted botulinum toxin inhibits hormone production in acromegaly.
Researchers at Michigan State University have identified a key protein called MLK3 that drives breast cancer cell migration and invasion. By targeting this protein, they hope to develop new therapies to prevent the spread of cancer.
The study suggests that eliminating the PSA test would result in more men being diagnosed with metastatic prostate cancer, leading to higher mortality rates. Prostate cancer death rates have been reduced by nearly 40% over the past 20 years, largely due to early detection through PSA testing.
The study found that without PSA testing, approximately 25,000 cases of advanced prostate cancer would occur in 2008, three times the actual number observed. This would result in more men experiencing aggressive disease with limited treatment options.
A recent study published in Cancer Biotherapy and Radiopharmaceuticals suggests that high-dose interleukin-2 (IL-2) should continue to be the initial treatment for patients with stage IV metastatic melanoma. The researchers recommend intensive IL-2 therapy as a viable option, either alone or in combination with newer therapeutic agents.
Researchers have identified RhoC as a key driver of breast cancer stem cell metastasis. High levels of RhoC are associated with worse patient survival rates. Targeting this molecule may lead to more effective treatments for certain types of cancer, potentially managing cancer stem cells and invasive behaviors.
Researchers at Vanderbilt University Medical Center found that stress activates the sympathetic nervous system, which promotes breast cancer cell colonization of bone. Beta-blockers, such as propranolol, can prevent this process by inhibiting sympathetic nervous system signals.
Physiologists and neuropathologists from the University of Zurich have identified the origin of metastasis formation in intestinal cancer cells. Cancer cells manipulate specific doorman receptors on blood vessel endothelium to enter other organs via bloodstream.
Researchers discovered that tumor cells release chemokine CCL2, which docks onto endothelial cells and activates the CCR2 receptor, making them permeable. This pathway enables tumor cells to migrate and metastasize.
Researchers create high-throughput flow-through optical microscope to classify rare breast cancer cells in blood samples, boasting a throughput of 100,000 cells per second. The technology demonstrates real-time identification of rare cancer cells with a record low false-positive rate.
A study published in Journal of Biological Chemistry found that prostate cancer cells lacking the protein SPDEF are unable to establish colonies at possible sites of metastasis, highlighting a potential biomarker for untreated cancers. Researchers hope to regulate SPDEF expression to prevent cancer cell metastasis.
Researchers analyzed genes expressed in circulating tumor cells and found increased expression of WNT2, a known oncogene, in CTCs from mouse models and human patients. Targeting the WNT2 pathway may reduce metastatic potential, which is critical for controlling pancreatic cancer.
Researchers discovered that NOG enables breast cancer cells to invade bone and establish tumors by increasing osteoclast activity and keeping cells in a stem-cell-like state. This gene plays a key role in the complex process of metastasis, increasing breast cancer's potential for spreading to the bone environment.
Research at Thomas Jefferson University discovered that senescent cells in the tumor microenvironment produce nutrients for cancer cells via autophagy, supporting their growth. This finding suggests that aging is a key factor in driving tumor growth and metastasis.
A new line of radioisotope therapy, Radium-223 chloride, has been shown to extend the lives of prostate cancer patients with advanced tumors that have spread to bone. The treatment has a short range of penetration and is usually well-tolerated, with serious side effects being rare.
Researchers at UNC Health Care identify a key genetic switch that determines melanoma's ability to spread. Inactivating the LKB1 gene causes non-aggressive cells to become highly metastatic.
Researchers have shown that CCR5 antagonists can prevent the migration and spread of breast cancer cells. Blocking CCR5 also reduces the formation of pulmonary metastases in mice with basal breast cancer, suggesting a new treatment option.
Researchers at VIB and KU Leuven discovered a novel mechanism for exosome formation involving Alix, syntenin, and syndecan proteins. This finding has implications for understanding the role of exosomes in cancer, metastasis, and other diseases.
A phase III trial found that men without liver metastases lived 8.2 months longer than those with metastasis, despite similar progression-free survival and response to chemotherapy.
Researchers discovered that cancer cells release exosomes containing pro-metastatic proteins that fuse with distant organs, establishing a nurturing environment for tumor growth. This discovery offers fresh diagnostic and treatment potential, including the use of exosomal protein profiles to predict tumor aggressiveness.
Dabrafenib, a BRAF inhibitor, demonstrates substantial tumor shrinkage in patients with brain metastases from melanoma. The study also reveals potential for the treatment to prolong survival beyond 12 months.
In a phase I clinical trial, dabrafenib successfully shrank tumors in 9 out of 10 patients with brain metastases. The drug also showed activity in other cancer types with the BRAF mutation. Researchers recommend an oral dose of 150 mg twice daily for future trials.
Researchers found that administering cyclophosphamide before bone tumors took root fertilized the bone marrow, enabling cancer cells to seed and grow. The study reversed this effect by inhibiting CCL2, suggesting a potential approach for preventing metastasis in certain cancers.
A randomized trial found that the ARCON regime improves control of cancer at its primary site, disease-free survival, and metastasis-free survival in patients with low Hb levels. However, overall survival remains compromised due to other health problems.
SPECT/CT scans have been shown to change clinical management in thyroid cancer patients by improving staging and risk stratification. The technology has been used both post-operatively and pre-ablation to identify metastatic lesions and adjust treatment approaches, leading to avoidance of unnecessary therapy.
Researchers at NYU College of Dentistry and UCSF will use genomic markers to identify oral cancer patients who don't need neck dissection. This study aims to improve quality of life and reduce recovery time for patients, potentially saving lives.
A Moffitt researcher has received a $100,000 grant from General Electric to develop a genetic tool that can identify an individual's predisposition to developing or resisting breast cancer metastasis. The study aims to evaluate inherited changes in DNA predictive of and identify risk for developing or resisting breast cancer metastasis.
Dr. Scott Waldman has received a CURE grant to develop a molecular diagnostic test that identifies patients who will benefit from adjuvant chemotherapy, reducing racial disparities in colon cancer mortality. The test uses guanylyl cyclase C as a biomarker and could help stratify patients into more targeted treatment groups.
The study found that overactivation of RANK signalling pathway promotes tumour stem cells, increasing tumour growth and metastasis in human breast epithelial cells. High levels of RANK protein are associated with poor prognosis tumours and basal type tumours.
Researchers study the origins of HIV/AIDS, revealing that SIV replication in human tissues is crucial to viral efficiency. In contrast, a new study finds that autoantibodies against citrullinated proteins contribute to bone loss in rheumatoid arthritis patients.
A new study found that a protein called SIX1 plays a critical role in early stage metastasis, especially lymphatic metastasis, in breast cancer. The study identified the SIX1-VEGF-C pathway as an important signaling pathway involved in breast cancer metastasis.
Researchers have identified metastasin as a crucial protein that helps stop tumor cells from spreading. By understanding how metastasin binds to motor proteins, scientists can develop drugs to block this interaction and prevent tumor cell proliferation.
Researchers discovered a novel signaling pathway involving SIX1 and VEGF-C that plays a crucial role in breast cancer metastasis. The study showed that this pathway can be targeted to develop new anti-cancer therapies.
Researchers created transgenic mice with light-emitting lymphatic vessels to study tumor cell dissemination. The technique detects lymph node invasion by tumor cells, providing a unique tool for studying inflammation and metastasis.
Percutaneous cryoablation, an interventional radiology procedure, uses tiny probes to freeze and destroy tumors in metastatic breast cancer. The treatment has been shown to provide a valuable alternative to other therapies with minimal side effects and reduced recovery time.
A phase 2 trial found that ipilimumab improved disease control and long-term survival in patients with advanced melanoma and brain metastases. The treatment was associated with similar immune-related side effects as those reported for patients without brain metastases, suggesting a potential new standard of care for this population.
Researchers are using pond scum microbes called Euglena to develop a new test for detecting cancer cells in the bloodstream. The test uses the microbe as a natural cargo carrier to identify and analyze circulating tumor cells, which enable cancer to spread.
Detecting circulating tumour cells in blood can provide information about breast cancer survival and help target treatment. Patients with high CTC counts have a higher risk of recurrence and death, while CTC detection may also become a target for future therapy.
Researchers found daily aspirin reduces risk of cancer death by 15% and cancer incidence by a quarter from 3 years onwards. Aspirin also shows promise in treating metastasis, with a 36% reduction in risk of distant cancer spread.
Researchers at the University of Kentucky have identified a key protein interaction that promotes metastasis in triple-negative breast cancer. Snail interacts with G9a to suppress E-cadherin expression, which is critical for cell adhesion and preventing tumor spread.
Cancer cells losing cadherin-11 protein spread to nearby organs and structures like lymph nodes. Researchers propose recovering protein activity could slow tumour growth and decrease metastases.
Researchers have found that Plexin-B1 represents a new candidate therapeutic target to treat patients with breast cancer found to overexpress the molecule ErbB-2. Overexpression of ErbB-2 led to activation of Plexin-B1, promoting metastatic cell characteristics in human breast cancer cells and reducing prognosis in human patients.
The new drug Vemurafenib doubles the median survival time of metastatic melanoma patients with a specific genetic mutation, from 6 months to 15.9 months. In responding patients, the drug stops cancer progression for an additional 6.7 months.
Dual inhibition of VEGF and c-MET signaling inhibits tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer. Inhibition of VEGF alone increases c-MET expression, leading to increased invasiveness and metastasis.
Scientists at UCSF found simultaneous targeting of two molecules can effectively shrink tumors, block invasion, and stop metastasis in mice. The approach may improve combination treatments, including drugs like Avastin, for various cancer types.
Researchers at UCSF have discovered a new class of drugs that target the mTOR protein, which is hyperactive in many forms of cancer. The new drugs block mTOR more completely than previous ones, effectively hobbles cancer cells and prevents metastasis.
Researchers at Weill Cornell Medical College found that a single protein, versican, is key to reversing the process of cancer metastasis in breast cancer. When versican was stopped from functioning, breast cancer could not seed itself into the lungs and form secondary tumors.
A study published in American Journal of Pathology reveals that trefoil factor 3 (TFF3) protein, which protects the epithelial surface in normal breast tissue, also promotes tumor invasion and metastasis in breast cancer. Higher TFF3 expression is associated with a more aggressive phenotype.
Researchers discovered that nonsteroidal anti-inflammatory drugs (NSAIDS) inhibit tumor metastasis by reducing lymphatic vessel dilation and prostaglandin pathways. This mechanism provides a potential target for cancer treatment.
Inflammatory breast cancer cells use the anti-inflammatory response of white blood cells to increase fibronectin expression, a molecule involved in wound healing and cell migration. Monocyte-conditioned media stimulate this process through the IL-8 signaling pathway, allowing cancer cells to branch and invade, leading to metastasis.
The American Society for Radiation Oncology (ASTRO) has developed a clinical practice guideline for the radiotherapeutic and surgical management of newly diagnosed brain metastases. The guideline provides evidence-based recommendations for choosing treatment modalities based on tumor factors and prognosis.
Researchers at Ohio State University have discovered a pattern of microRNAs that distinguishes early-stage breast tumors from deadly, invasive cancer. The findings suggest a potential biomarker for identifying high-risk DCIS tumors that may become invasive.
Research from the 2012 Genitourinary Cancers Symposium highlights promising new therapies for prostate cancer, including vigorous exercise and targeted drugs that improve survival rates. The studies also compare existing treatments, such as radiation therapy and hormone therapy, to determine their effectiveness.
Researchers at Scripps Research Institute found that a cell surface protein called CDCP1 protects tumor cells from apoptosis and promotes metastasis. The team identified plasmin as the key enzyme responsible for cleaving CDCP1, which triggers a signaling cascade blocking apoptosis and enabling cancer cells to colonize distant organs.
A new molecular test can predict the likelihood of death from early-stage lung cancer with greater accuracy than traditional methods. The test, which measures gene activity in cancerous tissue, has been shown to improve prognosis and guide treatment decisions for patients with non-squamous non-small cell lung cancer.
Researchers at Wayne State University are investigating the role of c-kit in bone metastasis of prostate cancer. They aim to understand how factors from the bone stimulate the production of c-kit and its ligand in prostate cancer cells, facilitating their growth and survival.
Researchers at the University of Pennsylvania School of Medicine have discovered that pancreatic cancer cells in an animal model begin to spread before clinically obvious tumor tissue is detected. Inflammation plays a crucial role in enhancing cancer progression, leading to the entry of cancer cells into the bloodstream. The study used...
A new study finds that pericytes, a group of cells in the tumor microenvironment, play a crucial role in preventing cancer progression and metastasis. Researchers discovered that inhibiting these cells can inadvertently make tumors more aggressive and likely to spread.